Adverum_Primary_Medium.png
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
April 18, 2023 08:00 ET | Adverum Biotechnologies, Inc.
- Innovative Licensing and Access Pathway designation is intended to accelerate the regulatory review process in the United Kingdom - - Ixo-vec has also been granted Fast Track Designation by the...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
April 17, 2023 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
March 30, 2023 16:05 ET | Adverum Biotechnologies, Inc.
- Full enrollment of the LUNA trial anticipated in the second half of 2023 - - LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023 - - LUNA...
Adverum_Primary_Medium.png
Adverum Biotechnologies to Present at Upcoming Investor Conferences
February 27, 2023 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) --  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
November 10, 2022 16:05 ET | Adverum Biotechnologies, Inc.
- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
November 04, 2022 12:08 ET | Adverum Biotechnologies, Inc.
- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in...
Adverum_Primary_Medium.png
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
October 27, 2022 16:05 ET | Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum_Primary_Medium.png
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
September 30, 2022 16:45 ET | Adverum Biotechnologies, Inc.
- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision...